Fund Mojo help you discover the best fund managers, funds, and related information

Fund Intelligence | Best Managers | RYOIX Insights | RYOIX Score | RYOIX Performance | RYOIX News | RYOIX Allocation | RYOIX Holdings Change

Rydex Biotechnology Inv (RYOIX) Fund Ranking and Research

Ranking, Research and Recommendation of Rydex Biotechnology Inv (RYOIX) Fund

    Last Trade: $79.93 on 5/23/2017, Change: -0.10 (-0.12%)

 

Graph of Rydex Biotechnology Inv Fund (RYOIX) ManagerFund Manager - Michael P. Byrum

Fund Manager Information

Fund Manager Tenure: 19.2 years
Similar Funds: RYOAX  RYHIX 
Fund Family: Rydex Funds
Fund Category: Health
Fund Performance: May 30, 2016
Fundmojo Fund Grade: C (Score: 0.57)     (What does this score mean?)
Byrum is president and CIO of Rydex Investments, his employer since its foundation in 1993. He has ultimate responsibility for the management of the funds. He was named the president of Rydex Investments in 2004 and has served as chief investment officer since 2003. He was named Vice President of Portfolio for Rydex Investments in 1998, and Executive Vice President in 2000. Prior to joining Rydex Investments, Mr. Byrum worked for Money Management Associates, the investment adviser for Rushmore Funds, Inc. Prior to joining Rydex Advisors, LLC, Mr. Byrum worked for Money Management Associates, Rydex Advisors, LLC for Rushmore Funds, Inc. He holds a degree in finance from Miami University of Ohio and is a member of the CFA Institute and the Washington Society of Investment Analysts.  Get more insights on Michael P. Byrum

 

Graph of Rydex Biotechnology Inv Fund (RYOIX) ProfileRydex Biotechnology Inv Fund (RYOIX) Profile

Fund Profile and Description

Rydex Biotechnology Inv Fund seeks capital appreciation. Rydex Biotechnology Inv Fund invests substantially at least 80% of its net assets in equity securities of Biotechnology Companies that are traded in the United States and derivatives. Biotechnology Companies are engaged in the research, development, and manufacture of various biotechnology-cal products, services, and processes; manufacture and/or distribute biotechnological and biomedical products. It invests to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. Rydex Biotechnology Inv Fund is non-diversified.

 

Rydex Biotechnology Inv (RYOIX) Fund Strength What we like about Rydex Biotechnology Inv (RYOIX) Fund

Data for Rydex Biotechnology Inv Fund (RYOIX) as of May 30, 2016

  • Rydex Biotechnology Inv Fund (RYOIX) management has been with Rydex Biotechnology Inv Fund for 19.2 years
  • Rydex Biotechnology Inv Fund (RYOIX) has good Long-term performance (5-year return 18.93% vs 16.08% Health category median performance)
  • Rydex Biotechnology Inv Fund (RYOIX) ratio of up-years vs down years is greater than 2
  • Rydex Biotechnology Inv Fund (RYOIX) is a true no-load fund as it has no load and no 12b1 promotion, distributions, marketing expenses

Rydex Biotechnology Inv Fund (RYOIX) Weakness What we are cautious about Rydex Biotechnology Inv (RYOIX) Fund

Data for Rydex Biotechnology Inv Fund (RYOIX) as of May 30, 2016

  • Rydex Biotechnology Inv Fund (RYOIX) has a less-than-ideal short-term performance (1-year return -24.79% vs -12.93% Health category median performance)
  • Rydex Biotechnology Inv Fund (RYOIX) has a less-than-ideal mid-term performance (3-year return 13.18% vs 15.21% Health category median performance)
  • Rydex Biotechnology Inv Fund (RYOIX) has a Morningstar rating of 3 and below
  • Rydex Biotechnology Inv Fund (RYOIX) is less safe compared to its Health peers
  • Rydex Biotechnology Inv Fund (RYOIX) has an annual stock turnover rate of 107.00% that is higher than the Health average of 43.99%. This could mean Rydex Biotechnology Inv is more nimble, but also signal potential high tax impact and high trading fees
  • Rydex Biotechnology Inv Fund (RYOIX) is more volatile than its peers as it has a 3-year Standard Deviation of 26.4 that is higher than category average of 17.59
  • Rydex Biotechnology Inv Fund (RYOIX) has a higher expense ratio of 1.33% than its Health average of 1.32%
  • As a Health focused fund, Rydex Biotechnology Inv Fund (RYOIX) is less diversified and has inherited sector risks associated with the fund
See Rydex Biotechnology Inv Fund (RYOIX) performance details as of May 30, 2016

 

What do you think?

 

Compare Rydex Biotechnology Inv Fund (RYOIX)Compare with other top Health category mutual funds

Aadditional top Health mutual funds for your consideration

FundYear to Date1 Year3 year5 year
Rydex Biotechnology Inv-16.03-24.7913.1818.93
Fidelity Advisor Health Care A (FACDX)-5.84-13.4918.7717.80Compare
Hartford Healthcare A (HGHAX)-6.82-7.8017.3816.39Compare
Janus Global Life Sciences T (JAGLX)-7.78-15.8319.3919.37Compare

See top fund managers for Health Category Funds

 

Compare Rydex Biotechnology Inv Fund (RYOIX)Compare with Health category ETFs

Some Health ETFs for your consideration

ETFYear to DateOne YearThree Year
First Trust NYSE Arca Biotech ETF (FBT)000
SPDR S&P Health Care Equipment ETF (XHE)000
SPDR S&P Biotech ETF (XBI)000
PowerShares S&P SmallCap Health Care ETF (PSCH)000
PowerShares Dynamic Pharmaceuticals ETF (PJP)000

 

Graph of Rydex Biotechnology Inv Fund (RYOIX) Net Asset TrackingRydex Biotechnology Inv (RYOIX) Fund Net Asset

Track net asset change of Rydex Biotechnology Inv fund (RYOIX)

DateNet Asset
05/2016$367.24M
03/2016$362.80M
02/2016$372.56M
More historic net asset information on Rydex Biotechnology Inv Fund (RYOIX)

  

Graph of Rydex Biotechnology Inv Fund (RYOIX) Portfolio TrackingRydex Biotechnology Inv (RYOIX) Fund Portfolio Allocation

Track portfolio allocation change of Rydex Biotechnology Inv fund (RYOIX)

DateCashStockBondOther
04/20161.15%98.85%0%0%
03/20160.27%99.73%0%0%
01/20160.56%99.44%0%0%
Click here to see more historic asset allocation information on Rydex Biotechnology Inv Fund (RYOIX)

 

graph of Rydex Biotechnology Inv Fund (RYOIX) Top 10 Position TrackingTop 10 Holdings in Rydex Biotechnology Inv (RYOIX) Fund

Discover what Rydex Biotechnology Inv Fund (RYOIX) manager is buying

Apr 29, 2016
Amgen Inc. [5.82%]
Gilead Sciences, Inc. [5.57%]
AbbVie Inc. Common Stock [5.33%]
Celgene Corporation [4.78%]
Biogen Inc. [4.22%]
Regeneron Pharmaceuticals, Inc. [3.27%]
Alexion Pharmaceuticals, Inc. [3.06%]
Baxalta Incorporated Common Sto [2.86%]
Vertex Pharmaceuticals Incorpor [2.46%]
Mylan N.V. [2.24%]

Mar 30, 2016
Gilead Sciences, Inc. [6.05%]
Amgen Inc. [5.75%]
AbbVie Inc. Common Stock [5.21%]
Celgene Corporation [4.83%]
Biogen Inc. [4.2%]
Regeneron Pharmaceuticals, Inc. [3.29%]
Alexion Pharmaceuticals, Inc. [3.21%]
Baxalta Incorporated Common Sto [2.87%]
Illumina, Inc. [2.75%]
Mylan N.V. [2.6%]

Jan 30, 2016
Amgen Inc. [6.71%]
Gilead Sciences, Inc. [6.32%]
Celgene Corporation [5.39%]
Biogen Inc. [4.73%]
Regeneron Pharmaceuticals, Inc. [3.69%]
Mylan N.V. [3.33%]
Alexion Pharmaceuticals, Inc. [3.3%]
Endo International plc [3.08%]
AbbVie Inc. Common Stock [3%]
Illumina, Inc. [2.95%]
Click here for Stock Holding Change Map in Rydex Biotechnology Inv Fund (RYOIX)

  

Latest News on Rydex Biotechnology Inv (RYOIX) Fund

See what is happening with Rydex Biotechnology Inv Fund (RYOIX)

 

Rydex Biotechnology Inv Fund (RYOIX) Related ResourcesSee more information on Rydex Biotechnology Inv (RYOIX) Fund

Popular pages on Rydex Biotechnology Inv (RYOIX) Fund

  

Fund Mojo Newsletter

Fund Mojo on Facebook Follow FundMojo on Twitter Fund Update